TR200200034T2 - Büyüme hormonu formülasyonları. - Google Patents

Büyüme hormonu formülasyonları.

Info

Publication number
TR200200034T2
TR200200034T2 TR2002/00034T TR200200034T TR200200034T2 TR 200200034 T2 TR200200034 T2 TR 200200034T2 TR 2002/00034 T TR2002/00034 T TR 2002/00034T TR 200200034 T TR200200034 T TR 200200034T TR 200200034 T2 TR200200034 T2 TR 200200034T2
Authority
TR
Turkey
Prior art keywords
growth hormone
temperatures
aggregation
level
formulations
Prior art date
Application number
TR2002/00034T
Other languages
English (en)
Turkish (tr)
Inventor
Siebold Bernhard
Stevens John
Original Assignee
Grandis Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200200034(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916252.1A external-priority patent/GB9916252D0/en
Priority claimed from GBGB9918902.9A external-priority patent/GB9918902D0/en
Application filed by Grandis Biotech Gmbh filed Critical Grandis Biotech Gmbh
Publication of TR200200034T2 publication Critical patent/TR200200034T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
TR2002/00034T 1999-07-12 2000-07-11 Büyüme hormonu formülasyonları. TR200200034T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9916252.1A GB9916252D0 (en) 1999-07-12 1999-07-12 Growth hormone formulation
GBGB9918902.9A GB9918902D0 (en) 1999-08-12 1999-08-12 Growth hormone formulation

Publications (1)

Publication Number Publication Date
TR200200034T2 true TR200200034T2 (tr) 2002-05-21

Family

ID=26315757

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00034T TR200200034T2 (tr) 1999-07-12 2000-07-11 Büyüme hormonu formülasyonları.

Country Status (25)

Country Link
US (1) US20060029635A1 (cg-RX-API-DMAC7.html)
EP (1) EP1194170B1 (cg-RX-API-DMAC7.html)
JP (3) JP2003504346A (cg-RX-API-DMAC7.html)
KR (1) KR20020031388A (cg-RX-API-DMAC7.html)
CN (1) CN1360506A (cg-RX-API-DMAC7.html)
AR (1) AR024728A1 (cg-RX-API-DMAC7.html)
AT (1) ATE386501T1 (cg-RX-API-DMAC7.html)
AU (1) AU775107C (cg-RX-API-DMAC7.html)
BR (1) BR0013162A (cg-RX-API-DMAC7.html)
CA (1) CA2378949C (cg-RX-API-DMAC7.html)
CZ (1) CZ200260A3 (cg-RX-API-DMAC7.html)
DE (1) DE60038118T2 (cg-RX-API-DMAC7.html)
ES (1) ES2300268T3 (cg-RX-API-DMAC7.html)
HK (1) HK1046358A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0202189A3 (cg-RX-API-DMAC7.html)
IL (2) IL147253A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02000404A (cg-RX-API-DMAC7.html)
NO (1) NO20020151L (cg-RX-API-DMAC7.html)
NZ (1) NZ516507A (cg-RX-API-DMAC7.html)
PL (1) PL353238A1 (cg-RX-API-DMAC7.html)
SI (1) SI1194170T1 (cg-RX-API-DMAC7.html)
SK (1) SK252002A3 (cg-RX-API-DMAC7.html)
TR (1) TR200200034T2 (cg-RX-API-DMAC7.html)
TW (1) TWI247608B (cg-RX-API-DMAC7.html)
WO (1) WO2001003741A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) * 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
EP1536835A1 (en) * 2002-07-09 2005-06-08 Sandoz AG Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol
CA2516314C (en) * 2003-03-18 2012-01-03 Ares Trading Sa Liquid growth hormone formulation and process of preparation thereof
JP2007506683A (ja) * 2003-09-25 2007-03-22 カンジェーン コーポレイション ヒト成長ホルモン剤およびその調整方法と使用方法
WO2005063298A1 (en) * 2003-12-23 2005-07-14 Pharmacia Corporation Stable growth hormone liquid formulation
AU2005237775B2 (en) * 2004-04-07 2010-03-04 Ares Trading S.A. Liquid growth hormone formulation
US8293532B2 (en) 2009-03-26 2012-10-23 Dow AgroSciences, L.L.C. Method and apparatus for tissue transfer
EP2501367B1 (en) * 2009-11-17 2015-01-21 Ipsen Pharma S.A.S. Formulation for HGH and RHIGF-1 combination
EP2736490A1 (en) 2011-07-25 2014-06-04 Sandoz AG Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein
JP2013231030A (ja) * 2012-04-30 2013-11-14 Sun Pharmaceutical Industries Ltd リュープロリド注射剤
JP6001401B2 (ja) * 2012-09-28 2016-10-05 ユニ・チャーム株式会社 ウェットティッシュ用薬液及びウェットティッシュ
WO2017098798A1 (ja) 2015-12-10 2017-06-15 三菱瓦斯化学株式会社 光硬化性組成物及び光学材料
JP6172880B1 (ja) * 2017-02-01 2017-08-02 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
EP3811962A4 (en) * 2018-06-25 2022-03-16 JCR Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
EP4243770A1 (en) * 2020-11-16 2023-09-20 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled multi-dose injection devices without cloud point
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
EP0211601A3 (en) * 1985-07-30 1988-01-13 International Minerals And Chemical Corporation Stabilization of growth promoting hormones
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
WO1994003198A1 (en) * 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性ｇｒｆ経鼻投与製剤
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
DK0549694T3 (da) * 1990-09-21 1995-10-16 Novo Nordisk As Adaptertop
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
ES2169351T3 (es) * 1996-02-13 2002-07-01 Searle & Co Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物

Also Published As

Publication number Publication date
WO2001003741A1 (en) 2001-01-18
JP2014208656A (ja) 2014-11-06
PL353238A1 (en) 2003-11-03
EP1194170B1 (en) 2008-02-20
ATE386501T1 (de) 2008-03-15
US20060029635A1 (en) 2006-02-09
BR0013162A (pt) 2002-05-28
DE60038118T2 (de) 2009-03-05
IL147253A0 (en) 2002-08-14
JP5941496B2 (ja) 2016-06-29
CA2378949A1 (en) 2001-01-18
AU775107B2 (en) 2004-07-15
HUP0202189A2 (en) 2002-10-28
WO2001003741B1 (en) 2001-04-19
NO20020151L (no) 2002-03-12
AR024728A1 (es) 2002-10-23
TWI247608B (en) 2006-01-21
HK1046358A1 (zh) 2003-01-10
CA2378949C (en) 2015-03-31
JP2003504346A (ja) 2003-02-04
IL147253A (en) 2007-07-24
SI1194170T1 (sl) 2008-10-31
CN1360506A (zh) 2002-07-24
MXPA02000404A (es) 2004-05-21
NZ516507A (en) 2004-02-27
CZ200260A3 (cs) 2002-04-17
AU5997500A (en) 2001-01-30
KR20020031388A (ko) 2002-05-01
NO20020151D0 (no) 2002-01-11
SK252002A3 (en) 2002-06-04
HUP0202189A3 (en) 2003-07-28
EP1194170A1 (en) 2002-04-10
AU775107C (en) 2005-02-24
DE60038118D1 (de) 2008-04-03
JP2012051891A (ja) 2012-03-15
ES2300268T3 (es) 2008-06-16

Similar Documents

Publication Publication Date Title
TR200200034T2 (tr) Büyüme hormonu formülasyonları.
US12138248B2 (en) Formulations of bendamustine
AR040526A1 (es) Formulaciuones de hgh en alta concentracion que contienen fenol
CA2204263C (en) Germicidal detergent-iodine compositions including polyvinyl pyrrolidone and compatible nonionic surfactant complexors
NZ256542A (en) Germicidal detergent-iodine compositions
JPH07509719A (ja) ヒト成長ホルモン水性製剤
CZ307715B6 (cs) Způsob lyofilizace vodné farmaceutické formulace faktoru VIII prosté albuminu
CA2361392C (en) Premixed formulation of piperacillin sodium and tazobactam sodium injection
ATE554792T1 (de) Stabiles wachstumshormon-flüssigformulierung
CN102014920B (zh) 滴眼剂制剂及其应用
SA06270332B1 (ar) تكوين hFSF مائي
EP0284249A1 (en) Lyophilized lymphokine composition
CZ20022654A3 (cs) Farmaceutická kompozice, obsahující Pemetrexed společně s monothioglycerolem, L-cysteinem nebo kyselinou thioglykolovou
CA2463681A1 (en) Ready-to-use paracetamol injection solutions containing propylene glycol as the only cosolvent
ES2258062T3 (es) Composicion antihelmintica.
US20060257440A1 (en) Insecticidal composition
PL1664123T5 (pl) Wytwarzanie w dużej skali inhibitora proteinazy alfa-1 i jego zastosowanie
CN102526064A (zh) 含有分子内具有氟原子的前列腺素的制品
MX2022008949A (es) Formulacion de anticuerpos estable.
CA2306224C (en) Improved iodine antimicrobial compositions containing nonionic surfactants and halogen anions
JP2006508139A (ja) 冬の環境の間に乳房を消毒するための組成物および方法
JP4610154B2 (ja) 注射用製剤
EP0049731B1 (en) Anthelmintic imidazo(2,1-b)thiazole gel compositions
JPH0621060B2 (ja) 非経口投与用組成物
RU1427644C (ru) Антибактериальный комплекс дл санации спермы сельскохоз йственных животных